Effects of funding policy changes and health warnings on the use of erythropoiesis-stimulating agents

Journal of Oncology Practice

Volumn 8, Issue 3, 2012, Pages 179-183

  Weir, Matthew A ^a   Gomes, Tara ^a   Winquist, Eric ^a   Juurlink, David N ^a   Cuerden, Meaghan S ^a   Mamdani, Muhammad ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; ARTICLE; CANADA; CROSS-SECTIONAL STUDY; DRUG COST; DRUG SAFETY; DRUG USE; FUNDING; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; NATIONAL HEALTH INSURANCE; PRESCRIPTION; PUBLICATION; TIME SERIES ANALYSIS;

EID: 84867903218     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000287     Document Type: Article

References (22)

1. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 91:1616-1634, 1999 (Pubitemid 29479929)
2. Skillings JR, Sridhar FG, Wong C, et al: The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol 16:22-25, 1993 (Pubitemid 23074775)
3. Goodnough LT: Risks of blood transfusion. Anesthesiol Clin North America 23:241-252, v, 2005.
4. Steinbrook R: Erythropoietin, the FDA, and oncology. N Engl J Med 356(24):2448-2451, 2007
5. Horlen C, Malone R, Bryant B, et al: Frequency of inappropriate metformin prescriptions. JAMA 287:2504-2505, 2002
6. Masoudi FA, Wang Y, Inzucchi SE, et al: Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 290:81-85, 2003 (Pubitemid 37432869)
7. Smalley W, Shatin D, Wysowski DK, et al: Contraindicated use of cisapride: Impact of Food and Drug Administration regulatory action. JAMA 284:3036-3039, 2000 (Pubitemid 32014741)
8. Health Canada: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/ prof/-2007/aranesp-eprex-hpc-cps-eng.php
9. US Food and Drug Administration: Public Health Advisory: Erythropoiesis-Stimulating Agents. http://www.fda.gov/ForConsumers/ByAudience/ ForPatientAdvocates/HIVandAIDSActivities/ucm124262.htm. 6-18-2009
10. Ontario Ministry of Health and Long-Term Care: http://www.health.gov.on. ca/en/public/programs/drugs/programs/odb/odb.aspx
11. Juurlink DN, Mamdani MM, Lee DS, et al: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543-551, 2004 (Pubitemid 39025171)
12. Weir MA, Juurlink DN, Gomes T, et al: Beta-blockers, trimethoprim- sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: A nested case-control study. Clin J Am Soc Nephrol 5:1544-1551, 2010
13. Park-Wyllie LY, Juurlink DN, Kopp A, et al: Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 354:1352-1361, 2006
14. Juurlink DN, Gomes T, Lipscombe LL, et al: Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: Population based cohort study. BMJ 339:b2942, 2009
15. Statistics Canada: More Information on Dissemination Area (DA). http://www12.statcan.ca/census-recensement/2006/ref/dict/geo021a-eng.cfm
16. NorthEast SAS Users Group: Estimating Confidence Intervals Around Relative Changes in Outcomes in Segmented Regression Analyses of Time Series Data. Presented at the 15th Annual NorthEast SAS Users Group Conference, Buffalo, NY, September 29 to October 2, 2002
17. Frosch DL, Krueger PM, Hornik RC, et al: Creating demand for prescription drugs: A content analysis of television direct-to-consumer advertising. Ann Fam Med 5:6-13, 2007 (Pubitemid 46193203)
18. Bennett CL, Silver SM, Djulbegovic B, et al: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914-924, 2008 (Pubitemid 351397066)
19. Bohlius J, Schmidlin K, Brillant C, et al: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 373:1532-1542, 2009
20. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 23:5960-5972, 2005
21. Tonelli M, Hemmelgarn B, Reiman T, et al: Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: A meta-analysis. CMAJ 180:E62-E71, 2009
22. Levy AR, O'Brien BJ, Sellors C, et al: Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 10:67-71, 2003 (Pubitemid 37028596)